Improving human health everywhere.

Science without fear.

Seoul Immunogenicity and Tolerance Seminar
South Korea
March 4th, 2019

EpiVax Gives Back in 2018, Looks Forward to 2019!

Leslie J. De Groot MD, 1928-2018

Breaking News: FDA awards $1 million to EpiVax, CUBRC, to assess generic peptide drugs

PANDA: The Newest Product at EpiVax

EpiVax Oncology Completes a $1.2M Bridge Financing

We are dedicated to applying our tools (in-silico, in-vitro and in-vivo) to re-engineering therapeutic proteins and to designing new vaccines. Discover

We take pride in our ability to put our combined intelligence, experience, and creativity to work to improve human health. Open minds, creative thought and natural curiosity lead to paradigm shifts. Contact us today to learn more.

Corporate Office/Laboratory:
EpiVax, Inc.

188 Valley Street, Suite 424, Providence, RI 02909 USA
ph: 401.272.2123 fax: 401.272.7562